Nanochon closes $4M Series Seed Prime
Nanochon, a Washington, DC-based orthopedic device biotech company has raised $4 million in its series seed prime fundraising round.
The round was led by The University of Virginia Licensing and Ventures Group Seed Fund, with participation from Cultivate (MD), Alumni Venture Group, and Mountain State Capital, among others.
Nanochon intends to use the funds to initiate its first in human clinical trials in the US in 2024, deepen research and development efforts, expand the company’s patent profile and grow its team.
“We’re thrilled to close our funding round and begin our clinical program,” says Ben Holmes, CEO and co-founder. “Securing this funding is one step closer towards achieving Nanochon’s goals of eliminating the need for knee replacements, and greatly shifting the paradigm of arthritic joint care.”
Nanochon will initiate a phase I trial in the US this year for its patented knee implant Chondrograft™. The device requires only minimally invasive surgery to regrow damaged cartilage and bone to stave off the need for full knee replacements which are costly and have a long recovery time.
Holmes follows, “We’ve had fantastic success in our animal studies and we’re very optimistic about future implications in human knees and other joints.”
Nanochon is a biotech and medical device company focused on developing innovative orthopedic solutions. Chondrograft™ is a minimally-invasive implant that allows for immediate weight-bearing and motion – meaning less time spent recovering. Nanochon has the potential to deliver more successful and longer-lasting recovery for patients than current standard of care. Our mission is to develop a new approach to treat cartilage replacement and repair so that the hundreds of thousands of young, active patients with joint damage can return to their lifestyles without having to undergo costly and invasive short-term fixes.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240503575444/en/
Contact information
Benjamin Holmes, ben.holmes@nanochon.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces Publication of Phase 3 PROMIS I and II Study Results in The Lancet Respiratory Medicine Showing Efficacy Results of CMS I-neb in Patients with Non-Cystic Fibrosis Bronchiectasis Colonized with P. aeruginosa13.9.2024 11:00:00 CEST | Press release
Zambon, a multinational pharmaceutical company focused on innovating cure and care to improve people’s health and the quality of patients’ lives, today announced the online publication of its Phase 3 PROMIS-I and PROMIS-II studies in The Lancet Respiratory Medicinejournal. The PROMIS studies assessed the efficacy and safety of inhaled colistimethate sodium administered via the I-neb® Adaptive Aerosol Delivery System (“CMS I-neb”) as a treatment to reduce the frequency of pulmonary exacerbations in patients with Non-Cystic Fibrosis Bronchiectasis (NCFB) chronically colonized with P. aeruginosa over 12 months, compared to placebo. “The publication of these pivotal data in The Lancet Respiratory Medicine represents an important milestone in our commitment to developing innovative therapies for patients with severe respiratory diseases,” said Paola Castellani, Chief Medical Officer and R&D Head at Zambon. “For patients with NCFB, a condition with no approved treatment options, the results
Intelsat Signs Hybrid Media Deal Distributing Hearst Networks EMEA Content13.9.2024 09:00:00 CEST | Press release
Intelsat, operator of one of the world’s largest integrated satellite and terrestrial networks, successfully launched a hybrid television content distribution service to deliver Hearst Networks EMEA (formerly known as A+E Networks EMEA) channels to hundreds of points across Europe thanks to its seamless satellite-terrestrial connection. “Growing global media customers like Hearst Networks EMEA want to work with a single operator that can provide seamless connections from satellite to ground-based Internet Protocol distribution networks,” said Rhys Morgan, regional vice president, EMEA, Media and Networks. “Intelsat has visibility across the full distribution network, even when it spans multiple technologies and can enable customers to reach more end users.” In order to reach a wide group of viewers, content providers typically use multiple distribution mediums such as direct-to-home (DTH), cable and IPTV. Hearst Networks EMEA needed to maximize the reach of its flagship channels, The H
NATO Support and Procurement Agency Contracts SES’s O3b mPOWER for Secure Communications Services13.9.2024 08:30:00 CEST | Press release
The NATO Support and Procurement Agency (NSPA) has awarded SES a contract to deliver secure high-performance low-latency satellite services via its medium earth orbit (MEO) constellation, enabling global missions for NATO member government organisations, agencies and military. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240910404747/en/ NATO Support and Procurement Agency Contracts SES’s O3b mPOWER for Secure Communications Services (Photo: Business Wire) The MEO Global Services (MGS) award represents a three-year Indefinite Delivery/Indefinite Quantity (IDIQ) contract valued at USD 200M, with two one-year options. This is the first award under the Global Commercially Contracted Satellite Communications Support Partnership (GCC SATCOM SP) established by the U.S. and Luxembourg under the auspices of NSPA in 2022, opening a new era of space cooperation within NATO. The MGS will be available to all NATO countries, including
Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types13.9.2024 08:00:00 CEST | Press release
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company and its research collaborators will present data from several studies utilizing Guardant technology to advance precision oncology at the European Society for Medical Oncology Congress (ESMO) in Barcelona, Spain, Sept. 13-17, 2024. Data on the Guardant Reveal™ minimal residual disease test in locally advanced rectal cancer patients enrolled in the NO-CUT trial will be presented in a proffered paper session during Presidential Symposium III. Other presentations will include findings from studies evaluating Guardant360® for therapy selection in advanced breast cancer and other solid tumors, and the Guardant Infinity™ platform for response monitoring in advanced non-small cell lung cancer (NSCLC). “Our latest data featured at ESMO further highlight the value of Guardant’s technology in precision oncology and the critical role liquid biopsy can play in informing therapy selection and treatm
SamanTree Medical Achieves FDA Clearance for Histolog® Scanner, Ushering in a New Era of Tissue Imaging in the U.S.13.9.2024 08:00:00 CEST | Press release
SamanTree Medical, a leader in innovative surgical imaging solutions, today announced that it has received FDA 510(k) clearance of its Histolog® Scanner for imaging of the internal microstructure of tissues including, but not limited to, the identification of cells, vessels and their organization or architecture. This groundbreaking Swiss made device is designed to provide real-time, highresolution imaging of fresh tissue surfaces, offering surgeons and pathologists this information for excised tissue. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240912995435/en/ The Histolog Scanner in use for rapid visualization of fresh tissue microstructures. (Photo: SamanTree Medical) The Histolog® Scanner enables real-time, ultra-fast confocal microscopy, allowing for the immediate imaging of resected tissues. This advancement aims to enable physicians to improve their efficiency. “We are thrilled to introduce the Histolog® Scanner t
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom